Desensitization of brain insulin receptor Effect on glucose/energy and related metabolism
The overall majority of cases of Alzheimer disease are not caused by genetic abnormalities. A pluricausal etiology is assumed, and the age factor may be of pivotal significance. Aging leads to inherent changes in basic metabolic principles, including the functionally most important cerebral glucose/energy metabolism. Experimentally induced perturbation of the neuronal control over the glucose metabolism by means of intracerebroventricular administration of streptozotocin leads to cascade-like abnormalities in glucose breakdown and energy formation and in membrane phospholipid and monoaminergic catecholamine metabolism, which closely resemble the disturbances found in sporadic Alzheimer disease. It is concluded that this model is a good tool for in vivo study of the cellular events characteristic for this human neurodegenerative disorder.
KeywordsEntorhinal Cortex Cerebral Glucose Metabolism Cerebral Glucose Utilization Related Metabolism Sporadic Alzheimer Disease
Unable to display preview. Download preview PDF.
- Bowen DM, White P, Spillane J A, Goodhardt MJ, Curzon G, Iwangoff P, Meier-Ruge W, Davison AN (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet i: 11–14Google Scholar
- Czech C, Masters C, Beyreuther K (1994) Alzheimer’s disease and transgenic mice. J Neural Transm [Suppl] 44 (this volume)Google Scholar
- Gottfries CG (1990) Disturbance of the 5-hydroxy-tryptamine metabolism in brains from patients with Alzheimer’s dementia. J Neural Transm [Suppl] 30: 33–43Google Scholar
- Hoyer S (1992a) The biology of the ageing brain. Oxidative and related metabolism. Eur J Gerontol 1: 157–165Google Scholar
- Hoyer S, Prem L, Sorbi S, Amaducci L (1993) Stimulation of glycolytic key enzymes in cerebral cortex by insulin. NeuroReport 4: 991–993Google Scholar
- Kumar A, Schapiro MB, Grady C, Haxby JV, Wagner E, Salerno JA, Friedland RP, Rapoport SI (1991) High-resolution PET studies in Alzheimer’s disease. Neuropsy- chopharmacology 4: 35–46Google Scholar
- Marcus DL, deLeon M, Swerdlow R, Kaplan H, Tsai J, Freedman ML (1988) Decreased brain glucose metabolism in vivo and in microvessels in patients with Alzheimer’s disease. Clin Res 36: 486AGoogle Scholar
- Murphey DGM, Bottomley PA, Salerno JA, DeCarli C, Mentis MJ, Grady CL, Teichberg D, Giacometti KR, Rosenberg JM, Hardy CJ, Schapiro MB, Rapoport SI, Alger JR, Horwitz B (1993) An in vivo study of phophorus and glucose metabolism in Alzheimer’s disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatry 50: 341–349CrossRefGoogle Scholar
- Riederer P, Sofic E, Moll G, Freyberger A, Wichart I, Gsell W, Jellinger K, Heben- streit G, Youdim MBH (1990) Senile dementia of Alzheimer’s type and Parkinson’s disease: neurochemical overlaps and specific differences. In: Dostert P, Riederer P (eds) Early markers in Parkinson’s and Alzheimer diseases. Springer, Wien New York, pp 221–232 (New vistas in drug research, vol 1 )Google Scholar
- Storandt M, Bakman L, Baltes MM, Blass JP, Braak H, Gutzmann H, Hauw JJ, Hoyer S, Jorm AF, Kauss J, Kliegl R, Mountjoy CQ (1988) Relationships of normal aging and dementing diseases in later life. In: Henderson AS, Henderson JH (eds) Etiology of dementia of Alzheimer’s type. Wiley, Chichester, pp 231–239Google Scholar